Clinical Trials Logo

Anemia, Iron Deficiency clinical trials

View clinical trials related to Anemia, Iron Deficiency.

Filter by:

NCT ID: NCT05949437 Recruiting - Clinical trials for Iron Deficiency Anemia

Effect of Yoga Breathing Exercises Versus Aerobic Exercise on Hematological Parameters

Start date: July 17, 2023
Phase: N/A
Study type: Interventional

Is there effect of yoga breathing exercises versus aerobic exercise on hematological parameters in iron deficiency anemic females? The purpose of the study is to investigate the effect of yoga breathing exercises versus aerobic exercise on hematological parameters in iron deficiency anemic females

NCT ID: NCT05919472 Recruiting - Clinical trials for Iron Deficiency Anemia

Effects of Oral Iron Supplementation on Vaccine Response in Iron Deficient Kenyan Women

Start date: July 1, 2023
Phase: N/A
Study type: Interventional

Iron deficiency (ID) anemia (IDA) is a global public health problem, with the highest prevalence in Africa. Vaccines often underperform in low- and middle- income countries (LMIC), and undernutrition, including ID, likely plays a role. Recent studies have shown the importance of iron status in vaccine response. Intravenous iron given at time of vaccination improved response to yellow fever and COVID-19 vaccines in IDA Kenyan women. Whether oral iron treatment would have a similar beneficial effect on vaccine response is uncertain. Also, timing of oral iron treatment needs further investigation. The co-primary objectives of this study are to assess 1) whether IDA in Kenyan women impairs vaccine response, and whether oral iron treatment improves their response; 2) the timing of oral iron treatment to improve vaccine response (prior to vaccination vs at time of vaccination). We will conduct a double-blind randomized controlled trial in southern Kenya to assess the effects of iron supplementation on response to three single-shot vaccines: Johnson & Johnson COVID- 19 (JJ COVID-19), the quadrivalent meningococcal vaccine (MenACWY) and the typhoid Vi polysaccharide vaccine (Typhim Vi). Women with IDA will be recruited and randomly assigned to three study groups: group 1 (pre- treatment) will receive 100 mg oral iron as ferrous sulfate (FeSO4) daily on days 1-56; group 2 (simultaneous treatment) will receive matching placebo daily on days 1-28, and 200 mg oral iron as FeSO4 daily on days 29-56; and group 3 (control) will receive matching placebo daily on days 1-56. Women in all groups will receive the JJ COVID-19 vaccine, the MenACWY and the Typhim Vi vaccine on day 28. Cellular immune response and serology will be measured at 28 days after vaccination in all groups.

NCT ID: NCT05913414 Recruiting - Anemia Clinical Trials

Iron Isomaltide for Iron-deficiency Anemia Patients With Locally Advanced Nasopharyngeal Carcinoma

Start date: May 5, 2023
Phase: Phase 2
Study type: Interventional

Primary purposeļ¼š To evaluate the difference of hematopoietic response rate at 1 month after concurrent chemoradiotherapy between iron isomaltide and oral iron supplement for treating iron-deficiency anemia patients with locally advanced nasopharyngeal carcinoma. Secondary purpose: To evaluate the difference of hematopoietic response rate, tolerance, acute side effects, qualtiy of life at 2 months and 3 months after concurrent chemoradiotherapy between Iron Isomaltide and oral iron supplement for treating iron-deficiency anemia patients with locally advanced nasopharyngeal carcinoma.

NCT ID: NCT05836961 Recruiting - Clinical trials for Iron Deficiency Anemia

Impact of Benazir Nashonuma Program (BNP) on Maternal and Child Nutritional Status

Start date: February 1, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the impact of Benazir Nashonuma Program (BNP) which includes specialized nutritious food (SNF) augmented with specific reproductive health interventions during pregnancy on proportion of low birthweight babies and stunting among children, in low income setting of Pakistan. The study aims to answer if: 1. Utilization of Benazir Nashonuma Program (BNP) among pregnant women is effective in reducing the proportion of low birthweight babies, compared to pregnant women who are not utilizing the program, among low income setting population. 2. Utilization of Benazir Nashonuma Program (BNP) is effective in reducing the proportion of stunting among children, compared to those not utilizing the program, among low income setting population. Participants who are enrolled in the Benazir Nashonuma Program (receiving intervention) and those who are not enrolled (not receiving intervention) will be followed throughout pregnancy till delivery. After delivery mother-baby dyad will be followed for a period of 12 months. Compliance of supplementation will be measured, and outcomes (low birthweight and stunting) observed throughout the follow up.

NCT ID: NCT05806437 Recruiting - Clinical trials for Anemia, Iron Deficiency

Patient Blood Management in the Approach to Prosthetic Surgery [PBM(L4178)]

PBM(L4178)
Start date: June 1, 2023
Phase: N/A
Study type: Interventional

We have been well guided in the "Good use of blood" during major surgery for many years, reaching a percentage of 4% of patients transfused after elective prosthetic operations. Valid patient blood management must provide for the possibility of limiting/zeroing the transfusion risk dependent on preoperative anemia, and the national guideline on PBM (Patient blood management) also underlines this Hypothesis and relevance

NCT ID: NCT05804071 Recruiting - Clinical trials for Iron Deficiency Anemia of Pregnancy

Analysis of the Effect of Iron Supplements on Iron Deficiency Anemia in Pregnancy

Start date: March 28, 2023
Phase: Phase 4
Study type: Interventional

Subjects were tested for hemoglobin, ferritin, serum iron, transferrin saturation and reticulocyte count during routine prenatal examination at 24-26 weeks of gestation, and blood samples were taken for serum hepcidin detection in the laboratory and the values were recorded. Those who met the criteria were included in the study group, signed the informed consent form and randomized into groups, and were given different drug administration schemes (150mg orally every day, 300mg orally every day, 150mg orally every other day, 300mg orally every other day, intravenous). At the same time, each subject was given anemia diet education, and all subjects were given folic acid 400ug/d and vitamin C 0.5g/d orally during the treatment period. If the subjects were in the oral iron group, the same time of oral iron was determined as 20 o'clock ± 1 hour in the evening, and the oral iron was not taken with other drugs; If the subject is in the intravenous medication group, the medication is scheduled to be administered at a uniform time of 8 o'clock ± 1 hour in the morning. The above subjects were followed up. Hemoglobin, ferritin, serum iron, transferrin saturation and reticulocyte count were performed at 30-32 and 37 weeks of pregnancy and delivery, and blood samples were taken for serum hepcidin detection in the laboratory and the values were recorded. The adverse reactions were investigated with a questionnaire at the last prenatal examination before delivery. After full term delivery, the patient fills in the delivery information and enters it into the database. Finally, the data statistician and the above personnel used the blind method for statistical analysis and reached a conclusion.

NCT ID: NCT05793996 Recruiting - Clinical trials for Chronic Heart Failure

The Prevalence of Iron Deficiency and the Effectiveness of Ferinject® in Patients With HFpEF (ID-HFpEF)

ID-HFpEF
Start date: April 28, 2023
Phase: Phase 4
Study type: Interventional

Observational cohort randomized controlled study to study the influence of correction of ID by intravenous injection of ferric carboxymaltose (Ferinject®) on quality of life indicators, functional status in a cohort of patients with HFpEF.

NCT ID: NCT05697211 Recruiting - Clinical trials for Anemia, Iron Deficiency

ORal IrON Supplementation With Ferric Maltol in Treating Iron Deficiency and Anaemia in Patients With Heart Failure (ORION-HF)

Start date: February 21, 2023
Phase: Phase 4
Study type: Interventional

This is an open-label, single arm, multicenter pilot-study to explore the safety, tolerability and efficacy of oral iron supplementation with ferric maltol in treating iron deficiency and anaemia in patients with heart failure.

NCT ID: NCT05681871 Recruiting - Clinical trials for Iron Deficiency Anemia

South African Paediatric Surgical Outcomes Study 2

SAPSOS2
Start date: February 9, 2023
Phase: Phase 4
Study type: Interventional

Preoperative anaemia has been shown to be associated with worse outcomes after surgery in both adults and children. Limited research has been done on how common preoperative iron-deficiency anaemia (IDA) is in children and how best to treat it. Oral iron is a relatively cost-effective treatment for IDA. This study aims to show whether giving children with IDA oral iron for 6-12 weeks before their surgery significantly improves their haemoglobin.

NCT ID: NCT05628896 Recruiting - Clinical trials for Anemia, Iron-Deficiency

Efficacy of a Preoperative Anaemia Clinic in Patients Undergoing Elective Abdominal Surgery

Start date: June 1, 2020
Phase:
Study type: Observational [Patient Registry]

Efficacy of a preoperative anaemia clinic in patients undergoing elective abdominal surgery diagnosed with iron deficieny anaemia